



Panelist



Lorenzo Pellegrini, Ph.D.
Partner
Care Capital LLC

Dr. Pellegrini is a Partner at Care Capital, a life sciences venture capital firm based in Princeton with \$500 million under management. During his ten-year tenure at Care, Dr. Pellegrini was a co-founder of several portfolio companies, including Sentinella Pharmaceuticals, Sonkei Pharmaceuticals and Somnus Therapeutics. He currently serves on the board of Agile Therapeutics, Minerva Pharmaceuticals and Sentinella Pharmaceuticals, among others.

Before joining Care Capital, Dr. Pellegrini conducted pre- and post-doctoral research in the Department of Cell Biology at Yale University and at the Max-Planck-Institute for Brain Research in Frankfurt am Main. His original research work on neuronal signaling and receptor internalization was published in leading peer-reviewed scientific journals such as Nature, Cell, Neuron and PNAS.

Dr. Pellegrini received a Laurea in Chemistry, summa cum laude, from Università di Padova, Italy; a Ph.D. in Biochemistry from the Max-Planck-Institute for Brain Research, Frankfurt am Main, Germany; and an M.B.A. with Honors from the Wharton School of the University of Pennsylvania.